Kruti Joshi, MPH, MD

Prevalence, Incidence and Economic Burden of Schizophrenia Among Medicaid Beneficiaries

Background: Schizophrenia carries a substantial economic burden to healthcare systems and payers. This study aims to update the prevalence, incidence and economic burden of schizophrenia ...

Charmi Patel , BS , RN, BSN, MPH;

Maryia Zhdanava , MA;

Maria-Helene Lafeuille , MA;

Patrick Lefebvre , MA;

Aurélie Côté-Sergent , MSc;

Dominic Pilon , MA;

Dee Lin , PharmD, MS;

Kruti Joshi , MPH, MD;

11/22/2019

Characteristics of Patients with Major Depressive Disorder and Acute Suicidal Ideation or Behavior Initiated on Esketamine or Traditional Therapies in the United States

Abstract: BACKGROUND: Adults with major depressive disorder with acute suicidal ideation or behavior (SIB; MDSI) initiated on esketamine or traditional therapies were described to underst...

Kruti Joshi , MPH, MD;

01/19/2023

Journey of the Veteran Health Administration Population With Recent Schizophrenia Diagnosis: A Real-World Analysis of Treatment Patterns and Healthcare Burden

Background: Schizophrenia is a chronic mental disorder that affects ~0.3-0.7% of the population worldwide and poses a significant economic and societal burden. Objectives: To describe tr...

Charmi Patel , BS , RN, BSN, MPH;

Ahong Huang , BS , MS;

Li Wang , MS, MBA, PhD, MA;

Yoshita Paliwal , PhD;

Kruti Joshi , MPH, MD;

11/22/2019

Costs Associated with Work Productivity Loss of Patients with Treatment-Resistant Depression Treated with Esketamine Nasal Spray Versus Quetiapine Extended Release: ESCAPE-TRD Subgroup Analysis

Work productivity loss (WPL) outcomes were compared among patients with treatment-resistant depression randomized to esketamine nasal spray (ESK) versus quetiapine extended-release (QUE) ...

Kruti Joshi , MPH, MD;

10/26/2023

Prevalence of Pre-existing Conditions for Adverse Events and Potential Drug-Drug Interactions Associated with Augmentation Therapies among Patients with Treatment-Resistant Depression

BACKGROUND: Comorbidities complicate clinicians' efforts to manage major depressive disorder (MDD). Pre-existing conditions and drug-drug interactions (DDI) may limit the array of safe ph...

Leslie Citrome , MD;

Laura Morrison , MPH;

John J. Sheehan , PhD, MBA, RPh;

Carmine Rossi , PhD;

Maryia Zhdanava , MA;

Oliver Lopena , PharmD;

Patrick Lefebvre , MA;

Dominic Pilon , MA;

Kruti Joshi , MPH, MD;

Swapna Karkare , MS;

10/19/2020

Characteristics and Healthcare Burden of Patients With Schizophrenia Treated in a United States Integrated Healthcare System

Objective: Limited data are available on patient characteristics and healthcare burden of schizophrenia in a healthcare system. This analysis examined the characteristics and healthcare b...

Kruti Joshi , MPH, MD;

Felix Sanchez , MS;

Charmi Patel , BS , RN, BSN, MPH;

Rohan Mahabaleshwarkar , PhD;

Jesse Fishman , PharmD;

Timothy Hetherington , MS;

Constance Krull , MSPH;

Dee Lin , PharmD, MS;

Oleg Tcheremissine , MD;

11/22/2019

Understanding Patient Profiles among Medicaid Patients with Treatment-resistant Depression Initiated on Esketamine

Real-world data studies on esketamine use for treatment-resistant depression (TRD) in the US have previously focused on commercially-insured patients. In this study of Medicaid beneficiar...

Kruti Joshi , MPH, MD;

10/26/2023

The Impact of Once-Monthly Paliperidone Palmitate on Healthcare Utilization Among Patients With Schizophrenia Treated in an Integrated Healthcare System

Objective: A previous study demonstrated that patients with schizophrenia consumed substantial healthcare resources in an integrated healthcare system. This study evaluated healthcare uti...

Rohan Mahabaleshwarkar , PhD;

Jesse Fishman , PharmD;

Charmi Patel , BS , RN, BSN, MPH;

Todd Blair ;

Dee Lin , PharmD, MS;

Timothy Hetherington , MS;

Carmella Benson , MSc, MS, MSHP;

Pooja Palmer ;

Kruti Joshi , MPH, MD;

Constance Krull , MSPH;

Oleg Tcheremissine , MD;

10/08/2020

Recent Patterns of Relapse and Associated Costs in Schizophrenia Patients Initiating Atypical Antipsychotics

BACKGROUND: Data on the burden associated with schizophrenia relapse within the new treatment landscape is scarce. This study aims to identify relapse in schizophrenia and update their as...

Patrick Lefebvre , MA;

Dominic Pilon , MA;

Charmi Patel , BS , RN, BSN, MPH;

Dee Lin , PharmD, MS;

Kruti Joshi , MPH, MD;

Maria-Helene Lafeuille , MA;

Aurélie Côté-Sergent , MSc;

11/22/2019

Understanding Profiles of Patients with Treatment-resistant Depression by Stringency of Health Plan Prior Authorization Criteria for Approval of Esketamine

In the United States, some health plans have more stringent prior authorization (PA) criteria for esketamine insurance coverage for treatment-resistant depression (TRD), requiring more th...

Kruti Joshi , MPH, MD;

10/26/2023